Linda Yaccarino, who resigned as chief executive of Elon Musk’s X in July, has been appointed CEO of eMed Population Health, the Miami-based telehealth start-up said Tuesday. Her hiring comes less than a month after her departure from the social-media platform and marks her first move into health care following a career in advertising, including more than a decade at NBCUniversal. Founded in 2020, eMed initially gained traction with at-home Covid-19 tests and now runs a digital platform that manages use of GLP-1 drugs for obesity and type-2 diabetes. The company says its service—offering diagnostics, virtual consultations and physician-guided prescribing—can cut the cost of a weight-loss program by up to 50%. It had raised about $22 million through 2022 and employs fewer than 200 people. Yaccarino’s expertise in brand partnerships and digital revenue is expected to help eMed court large employers and government payers as it scales. “There is an opportunity to combine technology, lifestyle and data in a new powerful way through the digital channels that impact consumers directly,” she said in a statement announcing the move. Demand for GLP-1 medicines is surging; Goldman Sachs estimates 15 million U.S. adults could be taking anti-obesity drugs by 2030, with the market reaching roughly $100 billion in annual sales. Yaccarino’s appointment signals eMed’s intention to capture a larger share of that growth by pairing consumer-focused technology with her advertising and partnership track record.